Award
National Cancer Institute 5R01CA282906-02
Noncanonical activities of SETD7 in preventing prostate cancer progression and therapy resistance
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$419,124.00
Ceiling
$419,124.00
Awarded
December 12, 2025
Identifier
5R01CA282906-02
Research project awarded by the National Cancer Institute to study SETD7's role in prostate cancer progression and therapy resistance.
Description
This project aims to investigate the role of SETD7 in prostate cancer progression and resistance, with potential therapeutic implications.